Latest Articles and Analysis

COVID-19 strains public health efforts addressing HIV outbreaks, diverting resources from the domestic epidemic.

Post-PHE planning for Medicaid redetermination: extended timelines and navigator support for safety net care.

Study explores social-spatial networks and HIV/HCV diagnosis rates among homeless and injection drug users.

Nobel laureate's HCV vaccine development targeting 2029 offers hope alongside access equity challenges.

Explores the personal toll of patient advocacy, examining burnout and the need to support advocates.

WHO 2030 HCV elimination goal at risk; only 5 of 110 countries on track as COVID-19 disrupts progress.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

Overview of the 340B Drug Discount Program for patient advocates covering program history and key policy issues.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

COVID-19 disrupts STI surveillance as staff redeployment, testing shortages, and clinic closures create gaps.

Calls for restoring Obama-era guidance defining 340B patient protections and enforcement mechanisms.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

Examines CMS's rebate rule on copay accumulator programs that block patient assistance from counting toward deductibles.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.

Broken advocacy pipeline lacks investment in leadership development, compensation, and mentorship.

Explores technology innovations in HIV care including mobile apps and drone pharmacy delivery.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

Supreme Court allows states to ration hepatitis C care in prisons, setting dangerous precedent for incarcerated people.

Reviews Biden's first 100 days on healthcare: infrastructure, subsidies, harm reduction, and health equity.